Progenics Pharma (PGNX) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St rises as oil falls heading into US midterm elections, more earnings
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 6% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts PGNX Hot Sheet
Price: $4.10 --0%
Financial Fact:
Net income (loss) per share - diluted: 0.52
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
Net income (loss) per share - diluted: 0.52
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Progenics Pharma (NASDAQ: PGNX) reported Q4 EPS of ($0.10), $0.04 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $5.1 million versus the consensus estimate of $2.25 million.
For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley bearish on Coinbase, slashes target on weaker recovery
- Marriott (MAR) Tops Q3 EPS by 19c; Guides EPS Higher
- Marriott shares rise 3% in premarket trade after raising full-year forecast
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
